{'fraction_non_alphanumeric': 0.02664796633941094, 'fraction_numerical': 0.0182328190743338, 'mean_word_length': 4.758064516129032, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Chloroquine resistant vivax malaria in an infant: a report from India.

Plasmodium vivax is seen in tropical areas predominantly in southeast Asia and India. Infact, it forms 60–70% of cases of malaria in India1. Chloroquine resistant P. falciparum has been increasingly found, however, it still remains an effective drug in the treatment of P. vivax. WHO still recommends chloroquine as the first line treatment for benign vivax malaria2. The first chloroquine resistant isolates of P. vivax were reported from Indonesia and Papua New Guinea3. Chloroquine resistant P. vivax malaria was first reported in India in 19954,5. We report chloroquine resistant vivax malaria in an infant for the first time from India.